Synonym: 5-Acetylimino-4-methyl-ยท2-1,3,4-thiadiazoline-2-sulfonamide; N-(4-Methyl-2-sulfamoyl-Δ2-1,3,4-thiadiazolin-5-ylidene) acetamide; L 584601; N-[5-(Aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide
CAS Number: 554-57-4
Empirical Formula (Hill Notation): C5H8N4O3S2
Molecular Weight: 236.27
EC Number: 209-066-7
MDL Number: MFCD00083416
Linear Formula: C5H8N4O3S2
Product Type: Chemical
| assay |
≥98% (HPLC) |
| color |
white to beige |
| form |
powder |
| InChI |
1S/C5H8N4O3S2/c1-3(10)7-4-9(2)8-5(13-4)14(6,11)12/h1-2H3,(H2,6,11,12)/b7-4+ |
| InChI key |
FLOSMHQXBMRNHR-QPJJXVBHSA-N |
| mp |
208 °C (dec.) (lit.) |
| Quality Level |
100  |
| SMILES string |
CN1N=C(SC1=NC(C)=O)S(N)(=O)=O |
| solubility |
DMSO: 20 mg/mL, clear |
| storage condition |
protect from light |
| storage temp. |
2-8°C |
| Biochem/physiol Actions: |
Methazolamide has a plasma half-life of 14 hours in humans. Methazolamide has relatively good lipid solubility and low plasma protein binding ability. Thus, it diffuses into tissues and fluids much more readily than acetazolamide, another carbonic anhydrase inhibitor. Methazolamide has less side effects than acetazolamide. |
| Biochem/physiol Actions: |
Methazolamide is a cell-permeable and potent carbonic anhydrase (CA) inhibitor that is used in the treatment of glaucoma. Methazolamide is an insulin sensitizer that reduces hepatic glucose generation in animal models. |
| Other Notes: |
Light sensitive |
| Packaging: |
50 mg in glass bottle |
| Purity |
≥98% (HPLC) |
| mp |
208 °C (dec.) (lit.) |
| Storage Temp. |
2-8°C |
| UNSPSC |
12352200 |
GHS07,GHS08